Virpax Pharmaceuticals, Inc.
VRPX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,819,308 | $5,118 | $10,763 | $4,839 |
| G&A Expenses | $6,260,627 | $7,822 | $11,082 | $7,186 |
| SG&A Expenses | $6,260,627 | $7,822 | $11,082 | $7,186 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $2,750 | $194 | $62 |
| Operating Expenses | $12,079,935 | $15,690 | $21,845 | $12,026 |
| Operating Income | -$12,079,935 | -$15,690 | -$21,845 | -$12,026 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $12,710 | $500 | $194 | -$31 |
| Pre-Tax Income | -$12,067,225 | -$15,190 | -$21,651 | -$12,056 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,067,225 | -$15,190 | -$21,456 | -$12,149 |
| % Margin | – | – | – | – |
| EPS | -2,836.41 | -12.97 | -18.32 | -10.37 |
| % Growth | -21,769% | 29.2% | -76.7% | – |
| EPS Diluted | -2,836.41 | -12.97 | -18.32 | -10.37 |
| Weighted Avg Shares Out | 4,254 | 1,171 | 1,171 | 1,171 |
| Weighted Avg Shares Out Dil | 4,254 | 1,171 | 1,171 | 1,171 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | -$103,750 | $0 | $0 | $93 |
| Depreciation & Amortization | $91,040 | $500 | $18,345 | $12,026 |
| EBITDA | -$12,079,935 | -$14,689 | $0 | $0 |
| % Margin | – | – | – | – |